These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 24053656)

  • 1. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies.
    Prins MH; Lensing AW; Bauersachs R; van Bellen B; Bounameaux H; Brighton TA; Cohen AT; Davidson BL; Decousus H; Raskob GE; Berkowitz SD; Wells PS;
    Thromb J; 2013 Sep; 11(1):21. PubMed ID: 24053656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.
    Prins MH; Lensing AW; Brighton TA; Lyons RM; Rehm J; Trajanovic M; Davidson BL; Beyer-Westendorf J; Pap ÁF; Berkowitz SD; Cohen AT; Kovacs MJ; Wells PS; Prandoni P
    Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies.
    Wang Y; Wang C; Chen Z; Zhang J; Liu Z; Jin B; Ying K; Liu C; Shao Y; Jing Z; Meng IL; Prins MH; Pap AF; Müller K; Lensing AW;
    Thromb J; 2013 Dec; 11(1):25. PubMed ID: 24341332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy.
    Wells PS; Gebel M; Prins MH; Davidson BL; Lensing AW
    Thromb J; 2014; 12():26. PubMed ID: 25698905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE program.
    Yamada N; Hirayama A; Maeda H; Sakagami S; Shikata H; Prins MH; Lensing AW; Kato M; Onuma J; Miyamoto Y; Iekushi K; Kajikawa M
    Thromb J; 2015; 13():2. PubMed ID: 25717286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment.
    Bauersachs RM; Lensing AW; Prins MH; Kubitza D; Pap ÁF; Decousus H; Beyer-Westendorf J; Prandoni P
    Thromb J; 2014; 12():25. PubMed ID: 25750589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral rivaroxaban for symptomatic venous thromboembolism.
    ; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
    N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies.
    Prandoni P; Prins MH; Cohen AT; Müller K; Pap ÁF; Tewes MC; Lensing AW
    Acad Emerg Med; 2015 Feb; 22(2):142-9. PubMed ID: 25676529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    ; Büller HR; Prins MH; Lensin AW; Decousus H; Jacobson BF; Minar E; Chlumsky J; Verhamme P; Wells P; Agnelli G; Cohen A; Berkowitz SD; Bounameaux H; Davidson BL; Misselwitz F; Gallus AS; Raskob GE; Schellong S; Segers A
    N Engl J Med; 2012 Apr; 366(14):1287-97. PubMed ID: 22449293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
    Bookhart BK; Haskell L; Bamber L; Wang M; Schein J; Mody SH
    J Med Econ; 2014 Oct; 17(10):691-5. PubMed ID: 25065536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
    Cohen AT; Dobromirski M
    Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
    Prandoni P
    Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
    Di Nisio M; Vedovati MC; Riera-Mestre A; Prins MH; Mueller K; Cohen AT; Wells PS; Beyer-Westendorf J; Prandoni P; Bounameaux H; Kubitza D; Schneider J; Pisters R; Fedacko J; Fontes-Carvalho R; Lensing AW
    Thromb Haemost; 2016 Sep; 116(4):739-46. PubMed ID: 27535349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.
    Monagle P; Lensing AWA; Thelen K; Martinelli I; Male C; Santamaría A; Samochatova E; Kumar R; Holzhauer S; Saracco P; Simioni P; Robertson J; Grangl G; Halton J; Connor P; Young G; Molinari AC; Nowak-Göttl U; Kenet G; Kapsa S; Willmann S; Pap AF; Becka M; Twomey T; Beyer-Westendorf J; Prins MH; Kubitza D;
    Lancet Haematol; 2019 Oct; 6(10):e500-e509. PubMed ID: 31420317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
    Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Haupt V; Schneider J; Turpie AG
    Thromb J; 2014; 12():16. PubMed ID: 25093014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban and the EINSTEIN clinical trial programme.
    Cohen AT; Bauersachs R
    Blood Coagul Fibrinolysis; 2019 Apr; 30(3):85-95. PubMed ID: 30920394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.